✦ LIBER ✦

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia

✍ Scribed by Hendrik W. van Deventer; Melissa D. Hall; Robert Z. Orlowski; Beverly S. Mitchell; Lee R. Berkowitz; Cathe Hogan; Cherie H. Dunphy; Julie Koehler; Thomas C. Shea

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 113 KB
Volume: 71
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.10215

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Persistent neutropenia in chronic myelog

Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.

Multicenter prospective trial evaluating

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?

✍ Yoshinobu Kanda; Shinichiro Okamoto; Tetsuzo Tauchi; Masahiro Kizaki; Koiti Inok 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japan

Molecular diagnosis and monitoring in th

Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

✍ Joyce Ou; Jo-Anne Vergilio; Adam Bagg 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 1 views

## Abstract The well‐established molecular pathogenesis of chronic myelogenous leukemia (CML) and its consequences for laboratory testing and clinical management illustrate a classic paradigm for the importance of molecular diagnostics in targeted drug therapy. The success of the tyrosine kinase in

Sustained remissions and low rate of BCR

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up

✍ Georg Hess; Ralf G. Meyer; Brigitte Schuch; Katja Bechthold; Ilse El-Kholy; Chri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 1 views

Reciprocal Relationship Between a Ph-Neg

Reciprocal Relationship Between a Ph-Negative Clone With Trisomy 8 Associated With Severe Myelodysplasia and a Ph-Positive Clone Following Imatinib Treatment in a Patient With Accelerated-Phase Chronic Myelogenous Leukemia (CML)

✍ Paulina Patchenko; Abraham Klepfish; Luba Trakhtenbrot; Rachel Rothman; Eliezer 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Cytarabine-Induced Neurotoxicity Responding to Methyl Prednisolone To the Editor: Neurotoxicity is a well-recognized complication following high-dose cytosine arabinoside (HIDAC). The pathophysiology of this toxicity is unknown, although an immune-mediated mechanism is hypothesized. We describe

Chronic myelogenous leukemia in nonlymph

Chronic myelogenous leukemia in nonlymphoid blastic phase : Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

✍ Stefano Sacchi; Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## BACKGROUND. The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of patients with nonlymphoid CML-BP is associated with very low response rates, a median survival of 2-3 months, and significant toxicities. The aim of this study was